News | November 23, 2024
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
CSPC will receive an upfront payment of $100 million from AstraZeneca
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Subscribe To Our Newsletter & Stay Updated
